GRHL2 and neoplasm: BoM+ patients had poor outcome for any efficacy end-point, irrespective of tumor histology, patient PS, concomitant spread into the liver or brain, or prior palliative radiotherapy in the bone, showing that organ-specific metastases are relevant factors in individual candidate to immunotherapy.